Lymphoma Follow-up
NCT00744120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51
Last updated 2013-12-20
Summary
This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.
Conditions
Sponsors & Collaborators
-
National Institute on Aging (NIA)
lead NIH
Principal Investigators
-
Patricia L. Duffey, RN · National Institute on Aging (NIA)
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-10-31
- Primary Completion
- 2013-09-30
- Completion
- 2013-09-30
Countries
- United States
Study Locations
More Related Trials
-
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
NCT06744075 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
NCT06674096 ·Status: RECRUITING ·Phase: PHASE2
-
Home Hospital for Lymphoma
NCT04423848 ·Status: TERMINATED ·Phase: NA
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
NCT05683171 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
NCT01715961 ·Status: COMPLETED ·Phase: NA
-
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065 ·Status: UNKNOWN
-
Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
NCT05600959 ·Status: NOT_YET_RECRUITING
-
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
NCT00001237 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
NCT06526065 ·Status: RECRUITING
-
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521 ·Status: RECRUITING ·Phase: NA
-
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
NCT00001512 ·Status: COMPLETED ·Phase: PHASE1
-
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
NCT00186355 ·Status: COMPLETED ·Phase: NA
-
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478 ·Status: COMPLETED
-
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
NCT00097565 ·Status: COMPLETED
-
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT03391466 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080 ·Status: RECRUITING ·Phase: PHASE2
-
Maintenance Hormonal Therapy and DLBCL
NCT06355401 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573 ·Status: RECRUITING ·Phase: NA
-
BRIEF Bendamustine and Rituximab In Elderly Follicular
NCT01313611 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
NCT05828589 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
NCT02660710 ·Status: COMPLETED ·Phase: PHASE2
-
Relmacabtagene Autoleucel in Patients With LBCL
NCT06142175 ·Status: RECRUITING
-
Autologous Vaccine for Follicular Lymphoma
NCT01022255 ·Status: COMPLETED ·Phase: PHASE1
-
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT01745354 ·Status: TERMINATED ·Phase: PHASE1
-
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733 ·Status: COMPLETED